• 1
    Savage L, Widener A. Sex hormones unrelated to prostate cancer risk. J Natl Cancer Inst 2008; 100: 157
  • 2
    Walsh PC. Physiological basis for hormonal therapy in carcinoma of the prostate. Urol Clin N Am 1975; 2: 257
  • 3
    Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000; 164: 7269
  • 4
    Tombal B. Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone? Eur Urol Suppl 2005; 4: 147
  • 5
    Esquena S, Abascal JM, Trilla E, Morote J. Failure of luteinising hormonal releasing hormonal agonist therapy to achieve castration. Does it exists? Eur Urol Suppl 2004; 3: 57 Abstract 218
  • 6
    Sarosdy MF, Schellhammer PF, Soloway MS, Vogelzang NJ, Crawford ED, Presti J. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int 1999; 83: 8016
  • 7
    Wechsel HW, Zerbib M, Pagano F, Coptcoat MJ. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostate cancer. Eur Urol 1996; 30: 714
  • 8
    McLeod D, Zinner N, Tomera K, Gleason D, Fotheringham N, Campion M. Abarelix study group. A phase 3, multicenter, open-label, randomised study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001; 58: 75661
  • 9
    Hussain M, Tangen CM, Higano C et al. Absolute prostate specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006; 24: 398490
  • 10
    Oosterlinck W, Mattelaer J, Casselman J. PSA evolution. A prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade; data from a Belgian multicentric study of 546 patients. Acta Urol Belg 1997; 65: 6371
  • 11
    Collette L, De Reijke TM, Schroder FH. Prostate specific antigen. A prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). Eur Urol 2003; 44: 1829
  • 12
    Collette L, Burzykowski T, Carroll KJ. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol 2005; 23: 613948
  • 13
    Arai Y, Yoshiki T, Yoshida O. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. J Urol 1990; 144: 14159
  • 14
    Cooper EH, Armitage TG, Robinson MR. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer. Cancer 1990; 66: 10258
  • 15
    Dijkman GA, Janknegt RA, De Reijke TM. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol 1997; 158: 1603
  • 16
    Debruyne FM, Dijkman GA, Lee DCH. A new long acting formulation of the luteinizing hormone-releasing hormone analogue, goserelin: results of studies in prostate cancer. J Urol 1996; 155: 13524
  • 17
    Jocham D. Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow up results. Urol Int 1998; 60 (Suppl. 2): 1824
  • 18
    Morote J, Orsola A, Planas J et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007; 178: 12905
  • 19
    Zlotta A, Debruyne FMJ. Expert opinion on optimal testosterone control in prostate cancer. Eur Urol Suppl 2005; 4: 379
  • 20
    Perachino M, Cavalli V, Ferraris V. Androgen deprivation therapy (ADT) and testosterone (T) in prostate cancer patients: the lower is really the better. Eur Urol Suppl 2008; 7: 204
  • 21
    Byar DP. The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate. Cancer 1973; 32: 112630